EP4240387A1 - Novel therapeutic composition based on essential oils at low doses - Google Patents
Novel therapeutic composition based on essential oils at low dosesInfo
- Publication number
- EP4240387A1 EP4240387A1 EP21816523.1A EP21816523A EP4240387A1 EP 4240387 A1 EP4240387 A1 EP 4240387A1 EP 21816523 A EP21816523 A EP 21816523A EP 4240387 A1 EP4240387 A1 EP 4240387A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- essential oil
- grams
- oil
- essential
- therapeutic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 258
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 230000001225 therapeutic effect Effects 0.000 title claims description 26
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 14
- 206010006451 bronchitis Diseases 0.000 claims abstract description 12
- 206010022000 influenza Diseases 0.000 claims abstract description 11
- 244000246386 Mentha pulegium Species 0.000 claims description 48
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 47
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 42
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 40
- 229940041616 menthol Drugs 0.000 claims description 36
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 34
- 241000723346 Cinnamomum camphora Species 0.000 claims description 33
- 229930008380 camphor Natural products 0.000 claims description 33
- 229960000846 camphor Drugs 0.000 claims description 33
- 235000014749 Mentha crispa Nutrition 0.000 claims description 26
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 26
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 26
- 241000723347 Cinnamomum Species 0.000 claims description 25
- 235000001167 Melaleuca cajuputi Nutrition 0.000 claims description 25
- 235000017710 Melaleuca viridiflora Nutrition 0.000 claims description 25
- 244000223014 Syzygium aromaticum Species 0.000 claims description 25
- 235000017803 cinnamon Nutrition 0.000 claims description 25
- 235000001050 hortel pimenta Nutrition 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 244000304222 Melaleuca cajuputi Species 0.000 claims description 24
- 235000008418 Hedeoma Nutrition 0.000 claims description 22
- 235000012629 Mentha aquatica Nutrition 0.000 claims description 22
- 244000173610 Mentha aquatica Species 0.000 claims description 22
- 239000008159 sesame oil Substances 0.000 claims description 19
- 235000011803 sesame oil Nutrition 0.000 claims description 19
- 244000024873 Mentha crispa Species 0.000 claims description 11
- 239000003708 ampul Substances 0.000 claims description 10
- 239000008157 edible vegetable oil Substances 0.000 claims description 10
- 239000000470 constituent Substances 0.000 claims description 9
- 239000004006 olive oil Substances 0.000 claims description 9
- 235000008390 olive oil Nutrition 0.000 claims description 9
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 206010035737 Pneumonia viral Diseases 0.000 claims description 2
- 208000009421 viral pneumonia Diseases 0.000 claims description 2
- 244000004281 Eucalyptus maculata Species 0.000 claims 7
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract description 4
- 208000038016 acute inflammation Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000005445 natural material Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 244000166124 Eucalyptus globulus Species 0.000 description 19
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 18
- 244000078639 Mentha spicata Species 0.000 description 15
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 12
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 12
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 12
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 9
- 229940087305 limonene Drugs 0.000 description 9
- 235000001510 limonene Nutrition 0.000 description 9
- 244000080208 Canella winterana Species 0.000 description 8
- 235000008499 Canella winterana Nutrition 0.000 description 8
- 229940017545 cinnamon bark Drugs 0.000 description 8
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 6
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 6
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 6
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 6
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 6
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 6
- 239000005770 Eugenol Substances 0.000 description 6
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 6
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 6
- IGODOXYLBBXFDW-UHFFFAOYSA-N alpha-Terpinyl acetate Chemical compound CC(=O)OC(C)(C)C1CCC(C)=CC1 IGODOXYLBBXFDW-UHFFFAOYSA-N 0.000 description 6
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 6
- 229940088601 alpha-terpineol Drugs 0.000 description 6
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 6
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 6
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 6
- 229960002217 eugenol Drugs 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010002653 Anosmia Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 235000019558 anosmia Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 4
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 3
- YGWKXXYGDYYFJU-SSDOTTSWSA-N (+)-menthofuran Chemical compound C1[C@H](C)CCC2=C1OC=C2C YGWKXXYGDYYFJU-SSDOTTSWSA-N 0.000 description 3
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 3
- SDOFMBGMRVAJNF-KVTDHHQDSA-N (2r,3r,4r,5r)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-KVTDHHQDSA-N 0.000 description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 3
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 3
- 239000001745 (6R)-3,6-dimethyl-4,5,6,7-tetrahydro-1-benzofuran Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 239000005973 Carvone Substances 0.000 description 3
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 3
- CKZXONNJVHXSQM-UHFFFAOYSA-N Ledol Natural products CC(C)C1CCC(C)(O)C2C3CC(C)CC123 CKZXONNJVHXSQM-UHFFFAOYSA-N 0.000 description 3
- YGWKXXYGDYYFJU-UHFFFAOYSA-N Menthofuran Natural products C1C(C)CCC2=C1OC=C2C YGWKXXYGDYYFJU-UHFFFAOYSA-N 0.000 description 3
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- TUWWTQRJWLLWJE-UHFFFAOYSA-N Viridiflorol Natural products CC1CCC2C1C3C(CCC2(O)O)C3(C)C TUWWTQRJWLLWJE-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- IGODOXYLBBXFDW-NSHDSACASA-N alpha-Terpinyl acetate Natural products CC(=O)OC(C)(C)[C@@H]1CCC(C)=CC1 IGODOXYLBBXFDW-NSHDSACASA-N 0.000 description 3
- PSVBPLKYDMHILE-UHFFFAOYSA-N alpha-humulene Natural products CC1=C/CC(C)(C)C=CCC=CCC1 PSVBPLKYDMHILE-UHFFFAOYSA-N 0.000 description 3
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- WJSDHUCWMSHDCR-VMPITWQZSA-N cinnamyl acetate Natural products CC(=O)OC\C=C\C1=CC=CC=C1 WJSDHUCWMSHDCR-VMPITWQZSA-N 0.000 description 3
- WGTRJVCFDUCKCM-UHFFFAOYSA-N ent-ledene Natural products C1CC2C(C)(C)C2C2C(C)CCC2=C1C WGTRJVCFDUCKCM-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 229930007744 linalool Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229930007503 menthone Natural products 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 150000007823 ocimene derivatives Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 3
- AYXPYQRXGNDJFU-IMNVLQEYSA-N viridiflorol Chemical compound [C@@H]1([C@@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-IMNVLQEYSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000021512 Cinnamomum verum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000203416 Melaleuca leucadendron Species 0.000 description 1
- 235000001136 Melaleuca leucadendron Nutrition 0.000 description 1
- 241000378544 Melaleuca quinquenervia Species 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000207961 Sesamum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000010684 cajeput oil Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- -1 cinnamaldhyde Chemical compound 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 239000001220 mentha spicata Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a composition of essential oils at low doses and its use for the treatment of influenza, acute bronchitis, inflammation and other infections of the respiratory tract.
- the pathogens responsible for respiratory tract infections are mostly viruses. Infections can affect the upper or lower part of the respiratory tract, although the latter area is more rarely affected but usually more severely. Thus, upper respiratory tract infections affect the nose, sinuses, pharynx and larynx. These infections include the flu and the common cold, for the most common of them. Lower respiratory tract infections affect the trachea, airways and lungs and are more common in children. Pneumonia and bronchitis are the most common forms of lower respiratory tract infections.
- viruses such as influenza
- influenza can cause infections in the upper and lower respiratory tract.
- the invention relates, in its broadest sense, to a therapeutic composition
- a therapeutic composition comprising a mixture of at least four essential oils for its use in the treatment of at least one respiratory infection, preferably chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular cinnamon bark essential oil, cajeput essential oil and camphor.
- the invention relates to a therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses and an excipient comprising at least one edible vegetable oil.
- the invention also relates to a therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses and an excipient comprising at least one edible vegetable oil, for its use orally for the treatment of influenza, acute bronchitis and other respiratory infections.
- essential oil it is generally understood that it is a liquid extract obtained (generally by distillation, for example with steam) from a plant and which typically concentrates its active ingredients. . In the context of the present invention, this expression also encompasses the active ingredients of these plants obtained synthetically.
- menthol is typically obtained by extracting a mint distillate (such as peppermint), but can also be synthesized.
- respiratory infection it is understood in the context of the present invention an infection affecting the structures of the respiratory system, namely the nose, the ears, the throat, the larynx, the trachea, the bronchi or the lungs.
- the pathogens responsible for respiratory tract infections are mostly viruses (i.e., they are therefore viral respiratory infections).
- low doses is understood in the context of the present invention doses that do not generate a toxic effect on the human body.
- the present invention therefore relates to the composition described above and its uses as described above.
- the composition can also be characterized in that: - the mixture of essential oils comprises at least five constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor; - the mixture of essential oils comprises all the constituents chosen from the list consisting of an essential oil of spearmint, menthol (crystals), an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor; - said composition is intended for oral administration; - said composition further comprises at least one edible vegetable oil as an excipient; - the excipient
- the mixture of essential oils comprises at least six constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor.
- the mixture of essential oils comprises at least seven constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor.
- the mixture of essential oils comprises at least eight constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor.
- the mixture of essential oils comprises at least nine constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor.
- said composition is intended for oral administration.
- composition according to the present invention can take any form suitable (solid or liquid) for such oral administration, such as in the form of tablets, capsules, capsules, powder, syrup, or drink, optionally by means of galenic form or device.
- providing sustained and/or delayed release such as a dissolution retardant coating.
- an agent such as cellulose, carbonates or starch is advantageously used.
- composition according to the present invention can be absorbed on any solid support allowing its incorporation into a solid or pasty formulation.
- the composition according to the present invention is in a liquid formulation.
- composition according to the present invention is suitable for being formulated in the form of an ampoule.
- composition according to the present invention is suitable for being formulated in the form of an ampoule with a volume of five milliliters to ten milliliters.
- the edible vegetable oil as an excipient can be a mixture of sesame oil and olive oil.
- the proportions of sesame oil: olive oil in the mixture can vary from 1:10 to 10:1 by weight, respectively.
- the proportions of sesame oil: olive oil in the mixture can vary from 1: 8 to 8: 1 by weight, from 1: 6 to 6: 1 by weight, from 1: 4 to 4: 1 by weight, 1:2 to 2:1 by weight or even 1:1 by weight respectively.
- composition according to the present invention may comprise between 5 grams and 8 grams of excipient, preferably between 6 grams and 7 grams, or even between 8 grams and 9 grams
- composition according to the present invention may comprise between 0.70 gram and 0.95 gram of a mixture of essential oils, preferably between 0.75 gram and 0.90 gram, or even between 0.80 gram and 0.85 grams of a blend of essential oils.
- the sum of the masses of excipient(s) (such as sesame oil) and the mixture of essential oils is between 5.62 grams and 10 grams, preferably between 6 grams and 9 grams, between 7 grams and 8 grams or even 10 grams.
- the proportions of the different essential oils in the composition according to the present invention can be reduced to a ratio between the minimum of each essential oil and the total weight of the composition: - between 0.4% and 1.42% by mass ratio of an essential oil of spearmint relative to the total weight of the composition; - between 0.50% and 1.60% by mass ratio of menthol relative to the total weight of the composition; - between 0.30%% and 1.24% in mass ratio of an essential oil of aquatic mint relative to the total weight of the composition, - between 0.20% and 1.07% in mass ratio of an essential oil of cloves relative to the total weight of the composition, - between 0.30% and 1.25% by mass ratio of an essential oil of peppermint relative to the total weight of the composition, - between 0.20% and 1.07% by mass ratio of an essential oil of pennyroyal relative to the total weight of the composition, - between 1.20% and 2.85% in mass ratio of an essential oil of eucalyptus relative to the total weight of the composition, - between 0.20% and 1.0
- the essential oil of spearmint comprises in the context of the present invention carvone and limonene, for example 40.8% carvone and 20.8% limonene.
- the menthol comprises in the context of the present invention menthol, for example 100% menthol.
- the essential oil of water mint comprises, in the context of the present invention, limonene, menthofuran, ocimene and beta-caryophyllene, for example 12.06% limonene, 51.26% menthofuran, 8.1% ocimene and 2.92% beta-caryophyllene.
- the clove essential oil comprises in the context of the present invention eugenol, beta-caryophyllene, alpha-humulene, eugenyl acetate, for example 76, 8% eugenol, 17.4% beta-caryophyllene, 2.1% alpha-humulene, 1.2% eugenyl acetate.
- the peppermint essential oil comprises, in the context of the present invention, menthol, menthone, 1,8 cineole, neo-menthol and menthyl acetate, for example 39.81% menthol, 19.55% menthone, 5.81% 1.8 cineole, 8.83% neo-menthol and 8.64% menthyl acetate.
- the essential oil of pennyroyal comprises in the context of the present invention menthol, pulegone, neo-menthol, for example 35.9% menthol, 23.2% pulegone, 9.2 % neo-menthol.
- the essential oil of eucalyptus comprises in the context of the present invention limonene, alpha terpineol, alpha terpinyl acetate, alpha pinene, for example 80.51% of limonene, 8.6% alpha terpineol, 6.07% alpha terpinyl acetate, 3.01% alpha pinene.
- the essential oil of cinnamon comprises in the context of the present invention eugenol, alpha pinene, cinnamaldhyde, cinnamyl acetate, linalool, for example 5.8% eugenol, 2 .6% alpha pinene, 76.8% cinnamaldhyde, 3.1% cinnamyl acetate, 2.4% linalool.
- the essential oil of cajeput comprises, in the context of the present invention, 1.8 cineole, viridiflorol, for example 21.3% of 1.8 cineole, 28.2% of viridiflorol.
- camphor comprises in the context of the present invention 1,8 cineole, alpha terpineol, camphor and safrole, for example 30.02% of 1,8 cineole, 5.22% of alpha terpineol, 36.61% camphor and 5.15% safrole.
- the sesame oil comprises in the context of the present invention linoleic acid, oleic acid, palmitic acid and stearic acid, for example 41% linoleic acid, 39% oleic acid, 8% palmitic acid and 5% stearic acid.
- the object of the present invention relates more particularly to a therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses and an excipient comprising at least one edible vegetable oil.
- the composition can also be characterized in that: - the excipient is sesame oil or olive oil; - the mixture of essential oils contains between two hundred and fifty milligrams and one gram, preferably between 0.6 grams and 1.0 gram of active substances (essential oils with menthol); - the mixture of essential oils includes an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor; - the mixture of essential oils comprises between 0.04 and 0.08 grams of an essential oil of spearmint, between 0.05 and 0.09 grams of menthol, between 0.03 and 0.07 grams of an essential oil essential oil of water mint, between 0.02 and 0.06 grams of an essential oil of cloves, between 0.03 and 0.07 grams of an essential oil of peppermint, between 0.02 and 0.06 grams of an
- the object of the present invention further relates to a therapeutic composition as described above, for its use orally for the treatment of influenza, acute bronchitis and other respiratory infections.
- the invention relates to a stimulant composed of an average dose of one gram distributed by weighting low doses of essential oils in a sesame oil excipient to facilitate their absorption.
- a stimulant composed of an average dose of one gram distributed by weighting low doses of essential oils in a sesame oil excipient to facilitate their absorption.
- the benefits of the content of these oils in active substances can be summarized as follows: 1) Essential Oil of Spearmint: Treatment of infections of the respiratory tract; 2) Menthol: Anti-inflammatory and antiviral action.
- Cajeput Oil in particular Cajeput Essential Oil: protects the nervous system and is an immune stimulant, anti-inflammatory and antioxidant recommended during epidemics; 10) Camphor: Has anti-inflammatory, antiseptic and anesthetic properties and is an immune stimulant and antioxidant recommended in times of epidemics; 11) Sesame Oil: excipient and facilitates absorption and is rich in vitamins E and B, magnesium and zinc.
- a composition is formed from a mixture of low doses of essential oils in a natural substance excipient to stimulate immunity. The total share of essential oils in this composition is one gram or less than one gram and the sesame oil excipient between four and nine grams. This composition is detailed in the following table.
- Table 1 essential oil blends covered COMPOSITION[] ESPECIALLY LATIN NAME GRAMS SPEARMINT ESSENTIAL OIL Mentha spicata 0.04 to 0.08 MENTHOL 0.05 to 0.09 WATER MINT ESSENTIAL OIL Menthae arvensis aetheroleum 0.03 to 0.07 CLOVE ESSENTIAL OIL Syzygium aromaticum 0.02 to 0.06 PEPPERMINT ESSENTIAL OIL Mentha piperita 0.03 to 0.07 POULIOT MINT ESSENTIAL OIL Mentha chicken 0.02 to 0.06 EUCALYPTUS ESSENTIAL OIL Eucalyptus globulus 0.12 to 0.16 CINNAMON (BARK) ESSENTIAL OIL Cinnamomum verum 0.02 to 0.06 CAJEPUT ESSENTIAL OIL Melaleuca leucadendron cajuputii 0.04 to 0.08 CAMPHOR, FOR EXAMPLE IN CRYSTALS OR ESSENTIAL OIL Cinnamo
- the dosage and the galenic form of the composition according to the present invention is adapted to the pathology and to the patient treated.
- the dosage may consist of a single dose, for example orally, in the case of influenza, acute bronchitis and other respiratory infections.
- the dosage may consist of a recurring daily, weekly or monthly intake of a single dose, for example orally, in the event of influenza, acute bronchitis and other respiratory infections.
- the quantity of formulation administered is adapted to the weight of the patient.
- composition according to the present invention is administered preventively, for example a single or recurring dose on a daily, weekly or monthly basis, for example orally.
- composition according to the present invention is administered to a population at risk.
- composition according to the present invention is administered to a population of an age greater than or equal to 40 years, greater than or equal to 50 years, greater than or equal to 60 years, greater than or equal to 70 years, greater than or equal to 80 years or greater than or equal to 90 years.
- Example 1 composition and toxicity
- Table 2 Realized Composition COMPOSITION GRAMS SPEARMINT ESSENTIAL OIL 0.08 MENTHOL 0.09 WATER MINT ESSENTIAL OIL 0.07 CLOVE ESSENTIAL OIL 0.06 PEPPERMINT ESSENTIAL OIL 0.07 POULIOT MINT ESSENTIAL OIL 0.06 EUCALYPTUS ESSENTIAL OIL 0.16 CINNAMON ESSENTIAL OIL 0.06 CAJEPUT ESSENTIAL OIL 0.08 CAMPHOR 0.27 QSP SESAME OIL 9
- the levels of the various constituents were measured: - the spearmint essential oil used comprised 40.8% carvone and 20.8% limonene; - the menthol used comprised 100% menthol; - the water mint essential oil used comprised 12.06% limonene, 51.26% menthofuran, 8.1% ocimene and 2.92% beta-caryophyllene; - the clove essential oil used comprised 76.8% eugenol, 17.4% beta-caryophyllene, 2.1% alpha-humulene, 1.2% eugenyl acetate; - peppermint essential oil used included 39.81% menthol, 19.55% menthone, 5.81% 1.8 cineole, 8.83% neo-menthol and 8.64% menthyl acetate ; - the pennyroyal essential oil used comprised 35.9% menthol, 23.2% pulegone, 9.2% neo-menthol; - the eucaly
- the average age was 40 at the time of the tests with the oldest person being 77 years old and the youngest person being 27 years old.
- the composition (a single dose)
- none of the people developed a severe form of the disease. All were able to see an improvement in their condition.
- one patient presented persistent anosmia, the only symptom that persisted in his case, and another presented partial anosmia.
- Table 3 summarizes some aspects of the test performed and the results obtained: Number of patients Age range (years) Average age by bracket (years) Persistent negative effects after treatment Improvement: time observed after administration of a first improvement, if specified 0-24h 24h-48h 72 hours and more Unspecified 14 20-40 37 1 (anosmia) 1 1 1 11 3 40-60 50 1 (partial anosmia) 1 0 1 1 2 60-80 69 0 1 0 0 1 1
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- La présente invention concerne une composition d’huiles essentielles à faibles doses et son utilisation pour le traitement des grippes, bronchites aigues, inflammations et autres infections des voies respiratoires.The present invention relates to a composition of essential oils at low doses and its use for the treatment of influenza, acute bronchitis, inflammation and other infections of the respiratory tract.
- Les agents pathogènes responsables des infections des voies respiratoires sont la plupart du temps des virus. Les infections peuvent toucher la partie supérieure ou inférieure des voies respiratoires, bien que cette dernière zone soit plus rarement affectée mais généralement de façon plus sévère. Ainsi, les infections des voies respiratoires supérieures touchent le nez, les sinus, le pharynx et le larynx. Ces infections incluent la grippe et le rhume, pour les plus courantes d’entre elles. Les infections des voies respiratoires inférieures touchent la trachée, les voies aériennes et les poumons et sont plus fréquentes chez les enfants. La pneumonie et la bronchite sont les formes les plus courantes d'infections des voies respiratoires inférieures.The pathogens responsible for respiratory tract infections are mostly viruses. Infections can affect the upper or lower part of the respiratory tract, although the latter area is more rarely affected but usually more severely. Thus, upper respiratory tract infections affect the nose, sinuses, pharynx and larynx. These infections include the flu and the common cold, for the most common of them. Lower respiratory tract infections affect the trachea, airways and lungs and are more common in children. Pneumonia and bronchitis are the most common forms of lower respiratory tract infections.
- Ainsi, certains virus, tel que celui de la grippe, peuvent provoquer des infections dans les voies respiratoires supérieures et inférieures.Thus, some viruses, such as influenza, can cause infections in the upper and lower respiratory tract.
- La propagation des virus passe principalement par les sécrétions nasales provenant de personnes infectées, qui contaminent leurs mains et qui sont ensuite transmises, par exemple, à la bouche de personnes en bonne santé. Les symptômes du rhume sont légers et disparaissent généralement en 4 à 10 jours.Viruses spread mainly through nasal secretions from infected people, which contaminate their hands and which are then transmitted, for example, to the mouths of healthy people. Cold symptoms are mild and usually disappear within 4 to 10 days.
- Dans ce contexte, l’épisode de pandémie de coronavirus 2 (Sars-CoV-2) a nécessité une réponse sanitaire rapide et efficace. Or, jusqu’à cet épisode, le développement et la mise sur le marché de produits antiviraux efficaces et sûrs se sont toujours révélés longs (pouvant prendre plusieurs années, voire décennies), voire fastidieux. Ainsi, les huiles essentielles, connues depuis longtemps pour contenir des agents antiviraux contre certains virus pathogènes, sont apparues comme des agents actifs candidats intéressants dans la préparation d’un produit pour lutter contre les infections des voies respiratoires et en particulier d’une infection liée au Sars-CoV-2.In this context, the coronavirus pandemic 2 (Sars-CoV-2) episode required a rapid and effective health response. However, until this episode, the development and marketing of effective and safe antiviral products have always proven to be long (which can take several years or even decades), even tedious. Thus, essential oils, known for a long time to contain antiviral agents against certain pathogenic viruses, have appeared as interesting candidate active agents in the preparation of a product for combating infections of the respiratory tract and in particular an infection linked to Sars-CoV-2.
- L’invention concerne, dans son acception la plus large, une composition thérapeutique comprenant un mélange d’au moins quatre huiles essentielles pour son utilisation dans le traitement d’au moins une infection respiratoire, préférentiellement choisies dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce, une huile essentielle de cajeput et du camphre.The invention relates, in its broadest sense, to a therapeutic composition comprising a mixture of at least four essential oils for its use in the treatment of at least one respiratory infection, preferably chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular cinnamon bark essential oil, cajeput essential oil and camphor.
- En outre, l’invention concerne une composition thérapeutique sous forme d’ampoule de volume cinq millilitres à dix millilitres comprenant des huiles essentielles à faible doses et un excipient comprenant au moins une huile végétale comestible.In addition, the invention relates to a therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses and an excipient comprising at least one edible vegetable oil.
- L’invention concerne également une composition thérapeutique sous forme d’ampoule de volume cinq millilitres à dix millilitres comprenant des huiles essentielles à faible doses et un excipient comprenant au moins une huile végétale comestible, pour son utilisation par voie orale pour le traitement des grippes, bronchites aigues et autres infections respiratoires.The invention also relates to a therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses and an excipient comprising at least one edible vegetable oil, for its use orally for the treatment of influenza, acute bronchitis and other respiratory infections.
- Par « huile essentielle », il est compris de manière générale qu’il s’agit d’un extrait liquide obtenu (généralement par distillation par exemple à la vapeur d’eau) à partir d’une plante et qui typiquement en concentre les actifs. Dans le contexte de la présente invention, cette expression englobe également les actifs de ces plantes obtenues de manière synthétique. Par exemple, le menthol est typiquement obtenu par extraction d’un distillat de menthe (telle que la menthe poivrée), mais peut aussi être synthétisé.By "essential oil", it is generally understood that it is a liquid extract obtained (generally by distillation, for example with steam) from a plant and which typically concentrates its active ingredients. . In the context of the present invention, this expression also encompasses the active ingredients of these plants obtained synthetically. For example, menthol is typically obtained by extracting a mint distillate (such as peppermint), but can also be synthesized.
- Par « infection respiratoire », il est compris dans le contexte de la présente invention une infection atteignant les structures du système respiratoire, à savoir le nez, les oreilles, la gorge, le larynx, la trachée, les bronches ou les poumons. Les agents pathogènes responsables des infections des voies respiratoires sont la plupart du temps des virus (i.e., il s’agit donc d’infections respiratoires virales).By "respiratory infection", it is understood in the context of the present invention an infection affecting the structures of the respiratory system, namely the nose, the ears, the throat, the larynx, the trachea, the bronchi or the lungs. The pathogens responsible for respiratory tract infections are mostly viruses (i.e., they are therefore viral respiratory infections).
- Par « à faible doses », est compris dans le contexte de la présente invention des doses ne générant pas d’effet toxique sur l’organisme humain.By "low doses", is understood in the context of the present invention doses that do not generate a toxic effect on the human body.
- La présente invention concerne donc la composition décrite ci-dessus et ses utilisations telles que décrites ci-dessus. The present invention therefore relates to the composition described above and its uses as described above.
- De manière préférée, la composition peut en outre être caractérisée en ce que :
- le mélange d’huiles essentielles comprend au moins cinq constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce, une huile essentielle de cajeput et du camphre ;
- le mélange d’huiles essentielles comprend tous les constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol (cristaux), une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce, une huile essentielle de cajeput et du camphre ;
- ladite composition est destinée à une administration par voie orale ;
- ladite composition comprend en outre au moins une huile végétale comestible en tant qu’excipient ;
- l’excipient est choisi parmi l’huile de sésame, l’huile d’olive ou un mélange des deux ;
- ladite composition comprend entre 4 grammes et 9 grammes d’excipient ;
- ladite composition est sous forme d’ampoule, telle qu’une ampoule de volume cinq millilitres à dix millilitres ;
- ladite composition comprend entre 0,62 gramme et 1,0 gramme d’un mélange d’huiles essentielles ;
- ladite composition comprend entre 0,04 et 0,08 grammes d’huile essentielle de menthe verte, entre 0,05 et 0,09 grammes de menthol, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe aquatique, entre 0,02 et 0,06 grammes d’une huile essentielle de clous de girofle, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe poivrée, entre 0,02 et 0,06 grammes d’une huile essentielle de menthe pouliot, entre 0,12 et 0,16 grammes d’une huile essentielle d’eucalyptus, entre 0,02 et 0,06 grammes d’une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce, entre 0,04 et 0,08 grammes d’une huile essentielle de cajeput et/ou entre 0,23 et 0,27 grammes de Camphre, et optionnellement entre 4 et 9 grammes d’huile végétale de sésame comestible en tant qu’excipient ;
- ladite composition comprend 0,08 grammes d’huile essentielle de menthe verte, 0,09 grammes de menthol, 0,07 grammes d’une huile essentielle de menthe aquatique, 0,06 grammes d’une huile essentielle de clous de girofle, 0,07 grammes d’une huile essentielle de menthe poivrée, 0,06 grammes d’une huile essentielle de menthe pouliot, 0,16 grammes d’une huile essentielle d’eucalyptus, 0,06 grammes d’une huile essentielle de cannelle, 0,08 grammes d’une huile essentielle de cajeput, et/ou 0,27 grammes de Camphre et optionnellement 9 grammes d’huile végétale comestible en tant qu’excipient ;
- l’excipient est choisi parmi l’huile de sésame, l’huile d’olive ou un mélange des deux ; et/ou
- l’infection respiratoire est choisie parmi la grippe, un rhume, une bronchite, telle qu’une bronchite aigue, une pneumopathie, telle qu’une pneumonie virale ou une pneumopathie liée au Sars-CoV-2.Preferably, the composition can also be characterized in that:
- the mixture of essential oils comprises at least five constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor;
- the mixture of essential oils comprises all the constituents chosen from the list consisting of an essential oil of spearmint, menthol (crystals), an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor;
- said composition is intended for oral administration;
- said composition further comprises at least one edible vegetable oil as an excipient;
- the excipient is chosen from sesame oil, olive oil or a mixture of the two;
- said composition comprises between 4 grams and 9 grams of excipient;
- said composition is in the form of an ampoule, such as an ampoule with a volume of five milliliters to ten milliliters;
- said composition comprises between 0.62 gram and 1.0 gram of a mixture of essential oils;
- said composition comprises between 0.04 and 0.08 grams of essential oil of spearmint, between 0.05 and 0.09 grams of menthol, between 0.03 and 0.07 grams of an essential oil of water mint , between 0.02 and 0.06 grams of a clove essential oil, between 0.03 and 0.07 grams of a peppermint essential oil, between 0.02 and 0.06 grams of a essential oil of pennyroyal, between 0.12 and 0.16 grams of an essential oil of eucalyptus, between 0.02 and 0.06 grams of an essential oil of cinnamon, in particular an essential oil of cinnamon bark, between 0.04 and 0.08 grams of a cajeput essential oil and/or between 0.23 and 0.27 grams of camphor, and optionally between 4 and 9 grams of edible sesame vegetable oil as an excipient ;
- said composition comprises 0.08 grams of essential oil of spearmint, 0.09 grams of menthol, 0.07 grams of an essential oil of aquatic mint, 0.06 grams of an essential oil of cloves, 0.07 grams of peppermint essential oil, 0.06 grams of pennyroyal essential oil, 0.16 grams of eucalyptus essential oil, 0.06 grams of cinnamon essential oil , 0.08 grams of an essential oil of cajeput, and/or 0.27 grams of camphor and optionally 9 grams of edible vegetable oil as an excipient;
- the excipient is chosen from sesame oil, olive oil or a mixture of the two; and or
- the respiratory infection is chosen from the flu, a cold, a bronchitis, such as an acute bronchitis, a pneumopathy, such as a viral pneumonia or a pneumopathy linked to Sars-CoV-2. - De manière préférée, le mélange d’huiles essentielles comprend au moins six constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, une huile essentielle de cajeput et du camphre.Preferably, the mixture of essential oils comprises at least six constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor.
- De manière plus préférée, le mélange d’huiles essentielles comprend au moins sept constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce , une huile essentielle de cajeput et du camphre.More preferably, the mixture of essential oils comprises at least seven constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor.
- De manière encore plus préférée, le mélange d’huiles essentielles comprend au moins huit constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, une huile essentielle de cajeput et du camphre.Even more preferably, the mixture of essential oils comprises at least eight constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor.
- De manière la plus préférée, le mélange d’huiles essentielles comprend au moins neuf constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, une huile essentielle de cajeput et du camphre.Most preferably, the mixture of essential oils comprises at least nine constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor.
- Dans un mode de réalisation, ladite composition est destinée à une administration par voie orale.In one embodiment, said composition is intended for oral administration.
- Ainsi, une composition selon la présente invention peut prendre toute forme adaptée (solide ou liquide) à une telle administration orale, telle que sous forme de comprimés, gélules, capsules, poudre, sirop, ou boisson, éventuellement au moyen de forme galénique ou dispositif assurant une libération prolongée et/ou retardée, tel qu’un revêtement retardateur de dissolution. Pour ce type de formulation assurant une libération prolongée et/ou retardée, on utilise avantageusement un agent tel que la cellulose, des carbonates ou de l'amidon.Thus, a composition according to the present invention can take any form suitable (solid or liquid) for such oral administration, such as in the form of tablets, capsules, capsules, powder, syrup, or drink, optionally by means of galenic form or device. providing sustained and/or delayed release, such as a dissolution retardant coating. For this type of formulation providing prolonged and/or delayed release, an agent such as cellulose, carbonates or starch is advantageously used.
- En effet, étant ab initia de forme liquide, la composition selon la présente invention, peut être absorbée sur tout support solide permettant son incorporation dans une formulation solide, ou pâteuse.Indeed, being ab initia in liquid form, the composition according to the present invention can be absorbed on any solid support allowing its incorporation into a solid or pasty formulation.
- De manière préférée, la composition selon la présente invention est en une formulation liquide.Preferably, the composition according to the present invention is in a liquid formulation.
- De manière préférée, la composition selon la présente invention est adaptée à être formulée sous forme d’ampoule.Preferably, the composition according to the present invention is suitable for being formulated in the form of an ampoule.
- De manière préférée, la composition selon la présente invention est adaptée à être formulée sous forme d’ampoule de volume cinq millilitres à dix millilitres.Preferably, the composition according to the present invention is suitable for being formulated in the form of an ampoule with a volume of five milliliters to ten milliliters.
- Dans un mode de réalisation particulier, l’huile végétale comestible en tant qu’excipient peut être un mélange d’huile de sésame et d’huile d’olive. Les proportions de l’huile de sésame : huile d’olive dans le mélange peuvent varier de 1 : 10 à 10 : 1 en poids, respectivement.In a particular embodiment, the edible vegetable oil as an excipient can be a mixture of sesame oil and olive oil. The proportions of sesame oil: olive oil in the mixture can vary from 1:10 to 10:1 by weight, respectively.
- Préférentiellement, les proportions de l’huile de sésame : huile d’olive dans le mélange peuvent varier de 1 : 8 à 8 : 1 en poids, de 1 : 6 à 6 : 1 en poids, de 1 : 4 à 4 : 1 en poids, de 1 : 2 à 2 : 1 en poids ou encore de 1 : 1 en poids respectivement.Preferably, the proportions of sesame oil: olive oil in the mixture can vary from 1: 8 to 8: 1 by weight, from 1: 6 to 6: 1 by weight, from 1: 4 to 4: 1 by weight, 1:2 to 2:1 by weight or even 1:1 by weight respectively.
- En outre, la composition selon la présente invention peut comprendre entre 5 grammes et 8 grammes d’excipient, préférentiellement entre 6 grammes et 7 grammes, ou encore entre 8 grammes et 9 grammes In addition, the composition according to the present invention may comprise between 5 grams and 8 grams of excipient, preferably between 6 grams and 7 grams, or even between 8 grams and 9 grams
- De plus, la composition selon la présente invention peut comprendre entre 0,70 gramme et 0,95 gramme d’un mélange d’huiles essentielles, préférentiellement entre 0,75 gramme et 0,90 gramme, ou encore entre 0,80 gramme et 0,85 gramme d’un mélange d’huiles essentielles. In addition, the composition according to the present invention may comprise between 0.70 gram and 0.95 gram of a mixture of essential oils, preferably between 0.75 gram and 0.90 gram, or even between 0.80 gram and 0.85 grams of a blend of essential oils.
- De manière préférée, la somme des masses d’excipient(s) (telle que l’huile de sésame) et le mélange d’huiles essentielles est compris entre 5,62 grammes et 10 grammes, préférentiellement compris entre 6 grammes et 9 grammes, entre 7 grammes et 8 grammes ou encore de 10 grammes.Preferably, the sum of the masses of excipient(s) (such as sesame oil) and the mixture of essential oils is between 5.62 grams and 10 grams, preferably between 6 grams and 9 grams, between 7 grams and 8 grams or even 10 grams.
- Ainsi les proportions des différentes huiles essentielles dans la composition selon la présente invention peuvent être ramené à un ratio entre le minima de chaque huile essentielle et le poids total de la composition :
- entre 0,4% et 1,42% en rapport massique d’une huile essentielle de menthe verte par rapport au poids total de la composition ;
- entre 0,50% et 1,60 % en rapport massique de menthol par rapport poids total de la composition ;
- entre 0,30%% et 1,24% en rapport massique d’une huile essentielle de menthe aquatique par rapport au poids total de la composition ,
- entre 0,20% et 1,07% en rapport massique d’une huile essentielle de clous de girofle par rapport au poids total de la composition ,
- entre 0,30% et 1,25% en rapport massique d’une huile essentielle de menthe poivrée par rapport au poids total de la composition ,
- entre 0,20% et 1,07% en rapport massique d’une huile essentielle de menthe pouliot par rapport au poids total de la composition ,
- entre 1,20% et 2,85% en rapport massique d’une huile essentielle d’eucalyptus par rapport au poids total de la composition ,
- entre 0,20% et 1,07% en rapport massique d’une huile essentielle de cannelle par rapport au poids total de la composition ,
- entre 0,40% et 1,42% en rapport massique d’une huile essentielle de cajeput par rapport au poids total de la composition , et/ou
- entre 2,30% et 4,81% en rapport massique de Camphre par rapport au poids total de la composition.Thus the proportions of the different essential oils in the composition according to the present invention can be reduced to a ratio between the minimum of each essential oil and the total weight of the composition:
- between 0.4% and 1.42% by mass ratio of an essential oil of spearmint relative to the total weight of the composition;
- between 0.50% and 1.60% by mass ratio of menthol relative to the total weight of the composition;
- between 0.30%% and 1.24% in mass ratio of an essential oil of aquatic mint relative to the total weight of the composition,
- between 0.20% and 1.07% in mass ratio of an essential oil of cloves relative to the total weight of the composition,
- between 0.30% and 1.25% by mass ratio of an essential oil of peppermint relative to the total weight of the composition,
- between 0.20% and 1.07% by mass ratio of an essential oil of pennyroyal relative to the total weight of the composition,
- between 1.20% and 2.85% in mass ratio of an essential oil of eucalyptus relative to the total weight of the composition,
- between 0.20% and 1.07% by mass ratio of an essential oil of cinnamon relative to the total weight of the composition,
- between 0.40% and 1.42% by mass ratio of an essential oil of cajeput relative to the total weight of the composition, and/or
- between 2.30% and 4.81% by mass ratio of Camphor relative to the total weight of the composition. - De manière préférée, l’huile essentielle de menthe verte comprend dans le contexte de la présente invention de la carvone et du limonène, par exemple 40,8% de carvone et 20,8% de limonène.Preferably, the essential oil of spearmint comprises in the context of the present invention carvone and limonene, for example 40.8% carvone and 20.8% limonene.
- De manière préférée, le menthol comprend dans le contexte de la présente invention du menthol, par exemple 100% de menthol.Preferably, the menthol comprises in the context of the present invention menthol, for example 100% menthol.
- De manière préférée, l’huile essentielle de menthe aquatique comprend dans le contexte de la présente invention du limonène, du menthofurane, de l’ocimène et de la béta-caryophyllène, par exemple 12,06% de limonène, 51,26% de menthofurane, 8,1% d’ocimène et 2,92% de béta-caryophyllène.Preferably, the essential oil of water mint comprises, in the context of the present invention, limonene, menthofuran, ocimene and beta-caryophyllene, for example 12.06% limonene, 51.26% menthofuran, 8.1% ocimene and 2.92% beta-caryophyllene.
- De manière préférée, l’huile essentielle de clous de girofle comprend dans le contexte de la présente invention de l’eugénol, de la béta-caryophyllène, de l’alpha-humulène, de l’acétate d’eugényle, par exemple 76,8% d’eugénol, 17,4% de béta-caryophyllène, 2,1% d’alpha-humulène, 1,2% d’acétate d’eugényle.Preferably, the clove essential oil comprises in the context of the present invention eugenol, beta-caryophyllene, alpha-humulene, eugenyl acetate, for example 76, 8% eugenol, 17.4% beta-caryophyllene, 2.1% alpha-humulene, 1.2% eugenyl acetate.
- De manière préférée, l’huile essentielle de menthe poivrée comprend dans le contexte de la présente invention du menthol, de la menthone, du 1,8 cinéole, du néo-menthol et du menthyl acétate, par exemple 39,81% de menthol, 19,55% de menthone, 5,81% de 1,8 cinéole, 8,83% de néo-menthol et 8,64% de menthyl acétate.Preferably, the peppermint essential oil comprises, in the context of the present invention, menthol, menthone, 1,8 cineole, neo-menthol and menthyl acetate, for example 39.81% menthol, 19.55% menthone, 5.81% 1.8 cineole, 8.83% neo-menthol and 8.64% menthyl acetate.
- De manière préférée, l’huile essentielle de menthe pouliot comprend dans le contexte de la présente invention du menthol, de la pulégone, du néo-menthol, par exemple 35,9% de menthol, 23,2% de pulégone, 9,2% de néo-menthol.Preferably, the essential oil of pennyroyal comprises in the context of the present invention menthol, pulegone, neo-menthol, for example 35.9% menthol, 23.2% pulegone, 9.2 % neo-menthol.
- De manière préférée, l’huile essentielle d’eucalyptus comprend dans le contexte de la présente invention du limonène, de l’alpha terpinéol, de l’acétate d’alpha terpinyle, de l’alpha pinène, par exemple 80,51% de limonène, 8,6% d’alpha terpinéol, 6,07% d’acétate d’alpha terpinyle, 3,01% d’alpha pinène.Preferably, the essential oil of eucalyptus comprises in the context of the present invention limonene, alpha terpineol, alpha terpinyl acetate, alpha pinene, for example 80.51% of limonene, 8.6% alpha terpineol, 6.07% alpha terpinyl acetate, 3.01% alpha pinene.
- De manière préférée, l’huile essentielle de cannelle comprend dans le contexte de la présente invention de l’eugénol, de l’alpha pinène, du cinnamaldhyde, du cinnamyl acétate, du linalool, par exemple 5,8% d’eugénol, 2,6% d’alpha pinène, 76,8% de cinnamaldhyde, 3,1% de cinnamyl acétate, 2,4% de linalool.Preferably, the essential oil of cinnamon comprises in the context of the present invention eugenol, alpha pinene, cinnamaldhyde, cinnamyl acetate, linalool, for example 5.8% eugenol, 2 .6% alpha pinene, 76.8% cinnamaldhyde, 3.1% cinnamyl acetate, 2.4% linalool.
- De manière préférée, l’huile essentielle de cajeput comprend dans le contexte de la présente invention du 1,8 cinéole, du viridiflorol, par exemple 21,3% de 1,8 cinéole, 28, 2% de viridiflorol.Preferably, the essential oil of cajeput comprises, in the context of the present invention, 1.8 cineole, viridiflorol, for example 21.3% of 1.8 cineole, 28.2% of viridiflorol.
- De manière préférée, le camphre comprend dans le contexte de la présente invention du 1,8 cinéole, de l’alpha terpinéol, du camphre et du safrole, par exemple 30,02% de 1,8 cinéole, 5,22% d’alpha terpinéol, 36,61% de camphre et 5,15% de safrole.Preferably, camphor comprises in the context of the present invention 1,8 cineole, alpha terpineol, camphor and safrole, for example 30.02% of 1,8 cineole, 5.22% of alpha terpineol, 36.61% camphor and 5.15% safrole.
- De manière préférée, l’huile de sésame comprend dans le contexte de la présente invention de l’acide linoléique, de l’acide oléique, de l’acide palmitique et de l’acide stéarique, par exemple 41% d’acide linoléique, 39% d’acide oléique, 8% d’acide palmitique et 5% d’acide stéarique.Preferably, the sesame oil comprises in the context of the present invention linoleic acid, oleic acid, palmitic acid and stearic acid, for example 41% linoleic acid, 39% oleic acid, 8% palmitic acid and 5% stearic acid.
- En outre, l’objet de la présente invention concerne plus particulièrement une composition thérapeutique sous forme d’ampoule de volume cinq millilitres à dix millilitres comprenant des huiles essentielles à faible doses et un excipient comprenant au moins une huile végétale comestible.In addition, the object of the present invention relates more particularly to a therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses and an excipient comprising at least one edible vegetable oil.
- De manière préférée, la composition peut en outre être caractérisée en ce que :
- l’excipient est l’huile de sésame ou l’huile d’olive ;
- le mélange des huiles essentielles contient entre deux cent cinquante milligrammes et un gramme, préférentiellement entre 0,6 grammes et 1,0 gramme des substances actives (les huiles essentielles avec le menthol) ;
- le mélange des huiles essentielles comprend une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce, une huile essentielle de cajeput et du camphre ;
- le mélange des huiles essentielles comprend entre 0,04 et 0,08 grammes d’une huile essentielle de menthe verte, entre 0,05 et 0,09 grammes de menthol, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe aquatique, entre 0,02 et 0,06 grammes d’une huile essentielle de clous de girofle, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe poivrée, entre 0,02 et 0,06 grammes d’une huile essentielle de menthe pouliot, entre 0,12 et 0,16 grammes d’une huile essentielle d’eucalyptus, entre 0,02 et 0,06 grammes d’une huile essentielle de cannelle, en particulier une huile essentielle de cannelle écorce, entre 0,04 et 0,08 grammes d’une huile essentielle de cajeput, entre 0,23 et 0,27 grammes de Camphre ; et/ou
- ladite composition comprend 0,08 grammes d’une huile essentielle de menthe verte, 0,09 grammes de menthol, 0,07 grammes d’une huile essentielle de menthe aquatique, 0,06 grammes d’une huile essentielle de clous de girofle, 0,07 grammes d’une huile essentielle de menthe poivrée, 0,06 grammes d’une huile essentielle de menthe pouliot, 0,16 grammes d’une huile essentielle d’eucalyptus, 0,06 grammes d’une huile essentielle de cannelle, 0,08 grammes d’une huile essentielle de cajeput, 0,27 grammes de Camphre et 9 grammes d’huile de sésame.Preferably, the composition can also be characterized in that:
- the excipient is sesame oil or olive oil;
- the mixture of essential oils contains between two hundred and fifty milligrams and one gram, preferably between 0.6 grams and 1.0 gram of active substances (essential oils with menthol);
- the mixture of essential oils includes an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, in particular an essential oil of cinnamon bark, an essential oil of cajeput and camphor;
- the mixture of essential oils comprises between 0.04 and 0.08 grams of an essential oil of spearmint, between 0.05 and 0.09 grams of menthol, between 0.03 and 0.07 grams of an essential oil essential oil of water mint, between 0.02 and 0.06 grams of an essential oil of cloves, between 0.03 and 0.07 grams of an essential oil of peppermint, between 0.02 and 0.06 grams of an essential oil of pennyroyal, between 0.12 and 0.16 grams of an essential oil of eucalyptus, between 0.02 and 0.06 grams of an essential oil of cinnamon, in particular an essential oil of cinnamon bark, between 0.04 and 0.08 grams of an essential oil of cajeput, between 0.23 and 0.27 grams of Camphor; and or
- said composition comprises 0.08 grams of an essential oil of spearmint, 0.09 grams of menthol, 0.07 grams of an essential oil of water mint, 0.06 grams of an essential oil of cloves , 0.07 grams of an essential oil of peppermint, 0.06 grams of an essential oil of pennyroyal, 0.16 grams of an essential oil of eucalyptus, 0.06 grams of an essential oil of cinnamon, 0.08 grams of cajeput essential oil, 0.27 grams of camphor and 9 grams of sesame oil. - L’objet de la présente invention concerne de plus une composition thérapeutique telle que décrite ci-dessus, pour son utilisation par voie orale pour le traitement des grippes, bronchites aigues et autres infections respiratoires.The object of the present invention further relates to a therapeutic composition as described above, for its use orally for the treatment of influenza, acute bronchitis and other respiratory infections.
- De manière plus particulière, l’invention concerne un stimulant composé d’une dose moyenne d’un gramme réparti en pondération de faibles doses d’huiles essentielles dans un excipient en huile de sésame pour faciliter leur absorption. Les bienfaits de la contenance de ces huiles en substances actives se résument comme suit :
1) Huile Essentielle de Menthe Verte : Traitement des infections des voies respiratoires ;
2) Menthol : Action anti-inflammatoires et antivirales.
3) Huile Essentielle de Menthe Aquatique : Propriétés Rafraichissantes ;
4) Huile Essentielle de Clous de Girofle : Actions Anti-infectieuses, antivirale, antibactérienne et stimulante immunitaire ;
5) Huile Essentielle de Menthe Poivrée : Actions contre les nausées, migraines, maux de tête et les douleurs rhumatismales, Rafraichissante et facilite la digestion ;
6) Huile Essentielle de Menthe Pouliot : Participe au bon fonctionnement hépatique ;
7) Huile Essentielle d’Eucalyptus : Rôle efficace contre l’irritation et l’assèchement pour soulage la sinusite et calme la toux grasse ;
8) Huile Essentielle de Cannelle, en particulier une huile essentielle de cannelle écorce: Actions anti-infectieuses, bactéricide et virucide. C’est un stimulant du système immunitaire ;
9) Huile de Cajeput, en particulier Huile Essentielle de Cajeput : protège le système nerveux et c’est un stimulant immunitaire, anti-inflammatoire et antioxydant recommandé en période d’épidémie ;
10) Camphre : Possède des propriétés anti-inflammatoires, antiseptiques et anesthésiques et c’est un stimulant immunitaire et antioxydant recommandé en période d’épidémie ;
11) Huile de Sésame : excipient et facilite l’absorption et est riche en vitamines E et B, en magnésium et en zinc.
Une composition est formée d’un mélange à faibles doses d’huiles essentielles dans un excipient en substance naturelle pour stimuler l’immunité. La part totale des huiles essentielles dans cette composition est d’un gramme ou bien inférieure à un gramme et l’excipient en huile de sésame entre quatre et neuf grammes. Cette composition est détaillée dans le tableau suivant.
[Table 1] : Tableau 1 : mélanges d’huiles essentielles couvertsCOMPOSITION[] PLUS PARTICULIEREMENT DE NOM LATIN GRAMMES HUILE ESSENTIELLE DE MENTHE VERTE Mentha spicata 0,04 à 0,08 MENTHOL 0,05 à 0,09 HUILE ESSENTIELLE DE MENTHE AQUATIQUE Menthae arvensis aetheroleum
0,03 à 0,07 HUILE ESSENTIELLE DE CLOUS DE GIROFLE Syzygium aromaticum 0,02 à 0,06 HUILE ESSENTIELLE DE MENTHE POIVREE Mentha piperita 0,03 à 0,07 HUILE ESSENTIELLE DE MENTHE POULIOT Mentha poulegium 0,02 à 0,06 HUILE ESSENTIELLE D’EUCALYPTUS Eucalyptus globulus 0,12 à 0,16 HUILE ESSENTIELLE DE CANNELLE (ÉCORCE) Cinnamomum verum 0,02 à 0,06 HUILE ESSENTIELLE DE CAJEPUT Melaleuca leucadendron cajuputii 0,04 à 0,08 CAMPHRE, PAR EXEMPLE EN CRISTAUX OU EN HUILE ESSENTIELLE Cinnamomum camphora 0,23 à 0,27 HUILE DE SESAME QSP Sesama 4 à 9
1) Essential Oil of Spearmint: Treatment of infections of the respiratory tract;
2) Menthol: Anti-inflammatory and antiviral action.
3) Aquatic Mint Essential Oil: Refreshing Properties;
4) Clove Essential Oil: Anti-infectious, antiviral, antibacterial and immune stimulating actions;
5) Peppermint Essential Oil: Actions against nausea, migraines, headaches and rheumatic pains, Refreshing and aids digestion;
6) Essential Oil of Pouliot Mint: Contributes to good liver function;
7) Eucalyptus Essential Oil: Effective role against irritation and dryness to relieve sinusitis and calm wet cough;
8) Essential Oil of Cinnamon, in particular an essential oil of cinnamon bark: Anti-infectious, bactericidal and virucidal actions. It is an immune system stimulant;
9) Cajeput Oil, in particular Cajeput Essential Oil: protects the nervous system and is an immune stimulant, anti-inflammatory and antioxidant recommended during epidemics;
10) Camphor: Has anti-inflammatory, antiseptic and anesthetic properties and is an immune stimulant and antioxidant recommended in times of epidemics;
11) Sesame Oil: excipient and facilitates absorption and is rich in vitamins E and B, magnesium and zinc.
A composition is formed from a mixture of low doses of essential oils in a natural substance excipient to stimulate immunity. The total share of essential oils in this composition is one gram or less than one gram and the sesame oil excipient between four and nine grams. This composition is detailed in the following table.
[Table 1]: Table 1: essential oil blends coveredCOMPOSITION[] ESPECIALLY LATIN NAME GRAMS SPEARMINT ESSENTIAL OIL Mentha spicata 0.04 to 0.08 MENTHOL 0.05 to 0.09 WATER MINT ESSENTIAL OIL Menthae arvensis aetheroleum
0.03 to 0.07 CLOVE ESSENTIAL OIL Syzygium aromaticum 0.02 to 0.06 PEPPERMINT ESSENTIAL OIL Mentha piperita 0.03 to 0.07 POULIOT MINT ESSENTIAL OIL Mentha chicken 0.02 to 0.06 EUCALYPTUS ESSENTIAL OIL Eucalyptus globulus 0.12 to 0.16 CINNAMON (BARK) ESSENTIAL OIL Cinnamomum verum 0.02 to 0.06 CAJEPUT ESSENTIAL OIL Melaleuca leucadendron cajuputii 0.04 to 0.08 CAMPHOR, FOR EXAMPLE IN CRYSTALS OR ESSENTIAL OIL Cinnamomum camphora 0.23 to 0.27 QSP SESAME OIL Sesama 4 to 9 - En ce qui concerne l’utilisation, de manière préférée la posologie et la forme galénique de la composition selon la présente invention est adaptée à la pathologie et au patient traitée.As regards the use, preferably the dosage and the galenic form of the composition according to the present invention is adapted to the pathology and to the patient treated.
- Par exemple, la posologie peut consister en une dose unique, par exemple par voie orale, en cas de grippe, bronchites aigues et autres infections respiratoires.For example, the dosage may consist of a single dose, for example orally, in the case of influenza, acute bronchitis and other respiratory infections.
- Alternativement, la posologie peut consister en une prise récurrente de manière quotidienne, hebdomadaire ou mensuelle d’une dose unique, par exemple par voie orale, en cas de grippe, bronchites aigues et autres infections respiratoires.Alternatively, the dosage may consist of a recurring daily, weekly or monthly intake of a single dose, for example orally, in the event of influenza, acute bronchitis and other respiratory infections.
- De manière préférée, la quantité de formulation administrée est adaptée au poids du patient.Preferably, the quantity of formulation administered is adapted to the weight of the patient.
- Dans un mode de réalisation particulier, la composition selon la présente invention est administrée de manière préventive, par exemple une dose unique ou récurrente de manière quotidienne, hebdomadaire ou mensuelle, par exemple par voie orale.In a particular embodiment, the composition according to the present invention is administered preventively, for example a single or recurring dose on a daily, weekly or monthly basis, for example orally.
- Dans un mode de réalisation particulier, la composition selon la présente invention est administrée à une population à risque.In a particular embodiment, the composition according to the present invention is administered to a population at risk.
- Dans un mode de réalisation particulier, la composition selon la présente invention est administrée à une population d’un âge supérieur ou égal à 40 ans, supérieur ou égal à 50 ans, supérieur ou égal à 60 ans, supérieur ou égal à 70 ans, supérieur ou égal à 80 ans ou encore supérieur ou égal à 90 ans.In a particular embodiment, the composition according to the present invention is administered to a population of an age greater than or equal to 40 years, greater than or equal to 50 years, greater than or equal to 60 years, greater than or equal to 70 years, greater than or equal to 80 years or greater than or equal to 90 years.
- Exemple 1 : composition et toxicitéExample 1: composition and toxicity
- On décrira ci-après, à titre d’exemple non limitatif, une forme d’exécution de la présente invention.An embodiment of the present invention will be described below, by way of non-limiting example.
- Un exemple de composition qui s’insère dans la configuration explicitée dans les revendications ci-dessus est résumé dans le tableau suivant.
[Table 2] Tableau 2 : Composition RéaliséeCOMPOSITION GRAMMES HUILE ESSENTIELLE DE MENTHE VERTE 0,08 MENTHOL 0,09 HUILE ESSENTIELLE DE MENTHE AQUATIQUE 0,07 HUILE ESSENTIELLE DE CLOUS DE GIROFLE 0,06 HUILE ESSENTIELLE DE MENTHE POIVREE 0,07 HUILE ESSENTIELLE DE MENTHE POULIOT 0,06 HUILE ESSENTIELLE D’EUCALYPTUS 0,16 HUILE ESSENTIELLE DE CANNELLE 0,06 HUILE ESSENTIELLE DE CAJEPUT 0,08 CAMPHRE 0,27 HUILE DE SESAME QSP 9
[Table 2] Table 2: Realized CompositionCOMPOSITION GRAMS SPEARMINT ESSENTIAL OIL 0.08 MENTHOL 0.09 WATER MINT ESSENTIAL OIL 0.07 CLOVE ESSENTIAL OIL 0.06 PEPPERMINT ESSENTIAL OIL 0.07 POULIOT MINT ESSENTIAL OIL 0.06 EUCALYPTUS ESSENTIAL OIL 0.16 CINNAMON ESSENTIAL OIL 0.06 CAJEPUT ESSENTIAL OIL 0.08 CAMPHOR 0.27 QSP SESAME OIL 9 - En outre, les taux des différents constituants ont été mesurés :
- l’huile essentielle de menthe verte utilisée comprenait 40,8% de carvone et 20,8% de limonène ;
- le menthol utilisé comprenait 100% de menthol ;
- l’huile essentielle de menthe aquatique utilisée comprenait 12,06% de limonène, 51,26% de menthofurane, 8,1% d’ocimène et 2,92% de béta-caryophyllène ;
- l’huile essentielle de clous de girofle utilisée comprenait 76,8% d’eugénol, 17,4% de béta-caryophyllène, 2,1% d’alpha-humulène, 1,2% d’acétate d’eugényle ;
- l’huile essentielle de menthe poivrée utilisée comprenait 39,81% de menthol, 19,55% de menthone, 5,81% de 1,8 cinéole, 8,83% de néo-menthol et 8,64% de menthyl acétate ;
- l’huile essentielle de menthe pouliot utilisée comprenait 35,9% de menthol, 23,2% de pulégone, 9,2% de néo-menthol ;
- l’huile essentielle d’eucalyptus utilisée comprenait 80,51% de limonène, 8,6% d’alpha terpinéol, 6,07% d’acétate d’alpha terpinyle, 3,01% d’alpha pinène ;
- l’huile essentielle de cannelle utilisée comprenait 5,8% d’eugénol, 2,6% d’alpha pinène, 76,8% de cinnamaldhyde, 3,1% de cinnamyl acétate, 2,4% de linalool ;
- l’huile essentielle de cajeput utilisée comprenait 21,3% de 1,8 cinéole, 28, 2% de viridiflorol ;
- le camphre utilisé comprenait 30,02% de 1,8 cinéole, 5,22% d’alpha terpinéol, 36,61% de camphre et 5,15% de safrole ; et
- l’huile de sésame utilisée comprenait 41% d’acide linoléique, 39% d’acide oléique, 8% d’acide palmitique et 5% d’acide stéarique.In addition, the levels of the various constituents were measured:
- the spearmint essential oil used comprised 40.8% carvone and 20.8% limonene;
- the menthol used comprised 100% menthol;
- the water mint essential oil used comprised 12.06% limonene, 51.26% menthofuran, 8.1% ocimene and 2.92% beta-caryophyllene;
- the clove essential oil used comprised 76.8% eugenol, 17.4% beta-caryophyllene, 2.1% alpha-humulene, 1.2% eugenyl acetate;
- peppermint essential oil used included 39.81% menthol, 19.55% menthone, 5.81% 1.8 cineole, 8.83% neo-menthol and 8.64% menthyl acetate ;
- the pennyroyal essential oil used comprised 35.9% menthol, 23.2% pulegone, 9.2% neo-menthol;
- the eucalyptus essential oil used comprised 80.51% limonene, 8.6% alpha terpineol, 6.07% alpha terpinyl acetate, 3.01% alpha pinene;
- the cinnamon essential oil used comprised 5.8% eugenol, 2.6% alpha pinene, 76.8% cinnamaldhyde, 3.1% cinnamyl acetate, 2.4% linalool;
- the cajeput essential oil used comprised 21.3% of 1.8 cineole, 28.2% of viridiflorol;
- the camphor used comprised 30.02% of 1.8 cineole, 5.22% of alpha terpineol, 36.61% of camphor and 5.15% of safrole; and
- the sesame oil used comprised 41% linoleic acid, 39% oleic acid, 8% palmitic acid and 5% stearic acid. - Aux taux indiqués dans les tableaux 1 et 2, l’ensemble des principes actifs cités ci-dessus sont en dessous de leur seuil DL50, confirmant que la solution ne présente aucun effet toxique particulier. At the levels indicated in Tables 1 and 2, all of the active ingredients mentioned above are below their LD50 threshold, confirming that the solution has no particular toxic effect.
- 19 patients infectés par Sars-CoV-2 ou présentant des symptômes pathologiques de Sars-CoV-2 (1 patient non vérifié par test PCR) ont pris la composition selon l’exemple 1 pendant la pandémie de Sars-CoV-2. Tous ces volontaires ont été informés sous couvert de confidentialité du contenu général de la composition et des risques éventuellement encourus (qui sont minimes vu le profil toxicologique de la composition). Aucun des volontaires n’était vacciné. 19 patients infected with Sars-CoV-2 or with pathological symptoms of Sars-CoV-2 (1 patient not verified by PCR test) took the composition according to Example 1 during the Sars-CoV-2 pandemic. All these volunteers were informed under cover of confidentiality of the general content of the composition and of the risks possibly incurred (which are minimal given the toxicological profile of the composition). None of the volunteers were vaccinated.
- La moyenne d’âge était de 40 ans au moment des tests avec comme personne la plus âgée une personne de 77 ans et comme personne la plus jeune une personne de 27 ans. Après la prise de la composition (une seule dose), aucune des personnes n’a développé de forme grave de la maladie. Tous ont pu constater une amélioration de leur condition. Néanmoins, un patient a présenté une anosmie persistante, seul symptôme ayant perduré dans son cas et un autre a présenté une anosmie partielle. Aucun autre patient n’a présenté d’autres symptômes post-infection dit « covid long ». Tous les patients ont alors été libres de résumer dans une attestation de témoignage médical, la description de leur propre état de santé avant et après administration de la composition selon l’Exemple 1.
[Table 3] Le tableau 3 résume quelques aspects du test effectué et des résultats obtenus :Nombre de patients Tranche d’âge (années) Moyenne d’âge par tranche (années) Effets négatifs persistants après traitement Amélioration : temps constaté après administration d’une première amélioration, si précisé 0-24h 24h-48h 72 h et plus Non précisé 14 20-40 37 1 (anosmie) 1 1 1 11 3 40-60 50 1 (anosmie partielle) 1 0 1 1 2 60-80 69 0 1 0 0 1
[Table 3] Table 3 summarizes some aspects of the test performed and the results obtained:Number of patients Age range (years) Average age by bracket (years) Persistent negative effects after treatment Improvement: time observed after administration of a first improvement, if specified 0-24h 24h-48h 72 hours and more Unspecified 14 20-40 37 1 (anosmia) 1 1 1 11 3 40-60 50 1 (partial anosmia) 1 0 1 1 2 60-80 69 0 1 0 0 1 - Plusieurs des patients ont par eux-mêmes constaté une amélioration très rapide de leur condition et l’ont précisé. Ce test semble donc montrer une activité bénéfique de la composition selon la présente invention, étant donné que les symptômes les plus graves (toux, difficultés dans la respiration, fièvre, etc.) ont disparus pour l’ensemble des patients ayant pris la composition selon l’invention. Seul l’un deux patients ont gardé comme symptôme une anosmie, dont l’une était partielle, qui n’est pas un symptôme létal à terme ou fortement handicapant.Several of the patients themselves saw a very rapid improvement in their condition and specified it. This test therefore seems to show a beneficial activity of the composition according to the present invention, given that the most serious symptoms (cough, difficulty in breathing, fever, etc.) disappeared for all the patients who took the composition according to the invention. Only one of the two patients retained an anosmia as a symptom, one of which was partial, which is not a lethal or highly disabling symptom.
Claims (20)
- Composition thérapeutique comprenant un mélange d’au moins quatre huiles essentielles pour son utilisation dans le traitement d’au moins une infection respiratoire.Therapeutic composition comprising a mixture of at least four essential oils for its use in the treatment of at least one respiratory infection.
- Composition thérapeutique selon la revendication 1, caractérisée en ce que le mélange d’huiles essentielles comprend au moins cinq constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, une huile essentielle de cajeput et du camphre, par exemple en cristaux ou sous forme d’huile essentielle de camphre.Therapeutic composition according to Claim 1, characterized in that the mixture of essential oils comprises at least five constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of of clove, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor, for example in crystals or in the form of an essential oil of camphor.
- Composition thérapeutique selon la revendications 2, caractérisée en ce que le mélange d’huiles essentielles comprend tous les constituants choisis dans la liste consistant en une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, une huile essentielle de cajeput et du camphre, par exemple en cristaux ou sous forme d’huile essentielle de camphre.Therapeutic composition according to Claim 2, characterized in that the mixture of essential oils comprises all the constituents chosen from the list consisting of an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of clove, an essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor, for example in crystals or in the form of essential oil of camphor.
- Composition thérapeutique selon l’une quelconque des revendications précédentes, caractérisée en ce que ladite composition est destinée à une administration par voie orale.Therapeutic composition according to any one of the preceding claims, characterized in that the said composition is intended for oral administration.
- Composition thérapeutique selon la revendication 4, caractérisée en ce que ladite composition comprend en outre au moins une huile végétale comestible en tant qu’excipient.Therapeutic composition according to claim 4, characterized in that said composition further comprises at least one edible vegetable oil as an excipient.
- Composition thérapeutique selon la revendication 5 caractérisée en ce que l’excipient est choisi parmi l’huile de sésame, l’huile d’olive ou un mélange des deux.Therapeutic composition according to Claim 5, characterized in that the excipient is chosen from sesame oil, olive oil or a mixture of the two.
- Composition thérapeutique selon l’une quelconque des revendications 4 à 6, caractérisée en ce que ladite composition comprend entre 4 grammes et 9 grammes d’excipient.Therapeutic composition according to any one of Claims 4 to 6, characterized in that the said composition comprises between 4 grams and 9 grams of excipient.
- Composition thérapeutique selon l’une quelconque des revendications 4 à 7, caractérisée en ce que ladite composition est sous forme d’ampoule, telle qu’une ampoule de volume cinq millilitres à dix millilitres.Therapeutic composition according to any one of Claims 4 to 7, characterized in that the said composition is in the form of an ampoule, such as an ampoule with a volume of five milliliters to ten milliliters.
- Composition thérapeutique selon l’une quelconque des revendications 4 à 8, caractérisée en ce que ladite composition comprend entre 0,60 gramme et 1,0 gramme d’un mélange d’huiles essentielles.Therapeutic composition according to any one of Claims 4 to 8, characterized in that the said composition comprises between 0.60 gram and 1.0 gram of a mixture of essential oils.
- Composition thérapeutique selon l’une quelconque des revendications précédentes, caractérisée en ce que ladite composition comprend entre 0,04 et 0,08 grammes d’huile essentielle de menthe verte, entre 0,05 et 0,09 grammes de menthol, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe aquatique, entre 0,02 et 0,06 grammes d’une huile essentielle de clous de girofle, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe poivrée, entre 0,02 et 0,06 grammes d’une huile essentielle de menthe pouliot, entre 0,12 et 0,16 grammes d’une huile essentielle d’eucalyptus, entre 0,02 et 0,06 grammes d’une huile essentielle de cannelle, entre 0,04 et 0,08 grammes d’une huile essentielle de cajeput et/ou entre 0,23 et 0,27 grammes de Camphre, par exemple en cristaux ou sous forme d’huile essentielle de camphre, et optionnellement entre 4 et 9 grammes d’huile végétale comestible en tant qu’excipient.Therapeutic composition according to any one of the preceding claims, characterized in that the said composition comprises between 0.04 and 0.08 grams of spearmint essential oil, between 0.05 and 0.09 grams of menthol, between 0, 03 and 0.07 grams of an essential oil of water mint, between 0.02 and 0.06 grams of an essential oil of cloves, between 0.03 and 0.07 grams of an essential oil of mint peppermint, between 0.02 and 0.06 grams of pennyroyal essential oil, between 0.12 and 0.16 grams of eucalyptus essential oil, between 0.02 and 0.06 grams of essential oil of cinnamon, between 0.04 and 0.08 grams of an essential oil of cajeput and/or between 0.23 and 0.27 grams of camphor, for example in crystals or in the form of essential oil of camphor, and optionally between 4 and 9 grams of edible vegetable oil as an excipient.
- Composition thérapeutique selon l’une quelconque des revendications précédentes, caractérisée en ce que ladite composition comprend 0,08 grammes d’huile essentielle de menthe verte, 0,09 grammes de menthol, 0,07 grammes d’une huile essentielle de menthe aquatique, 0,06 grammes d’une huile essentielle de clous de girofle, 0,07 grammes d’une huile essentielle de menthe poivrée, 0,06 grammes d’une huile essentielle de menthe pouliot, 0,16 grammes d’une huile essentielle d’eucalyptus, 0,06 grammes d’une huile essentielle de cannelle, 0,08 grammes d’une huile essentielle de cajeput, et/ou 0,27 grammes de Camphre et optionnellement 9 grammes d’huile végétale comestible en tant qu’excipient.Therapeutic composition according to any one of the preceding claims, characterized in that the said composition comprises 0.08 grams of essential oil of spearmint, 0.09 grams of menthol, 0.07 grams of an essential oil of water mint, 0.06 grams of an essential oil of cloves, 0.07 grams of an essential oil of peppermint, 0.06 grams of an essential oil of pennyroyal, 0.16 grams of an essential oil of eucalyptus, 0.06 grams of an essential oil of cinnamon, 0.08 grams of an essential oil of cajeput, and/or 0.27 grams of camphor and optionally 9 grams of edible vegetable oil as an excipient .
- Composition thérapeutique selon la revendication 10 ou 11 caractérisée en ce que l’excipient est choisi parmi l’huile de sésame, l’huile d’olive ou un mélange des deux.Therapeutic composition according to Claim 10 or 11, characterized in that the excipient is chosen from sesame oil, olive oil or a mixture of the two.
- Composition thérapeutique selon l’une quelconque des revendications précédentes, caractérisée en ce que l’infection respiratoire est choisie parmi la grippe, un rhume, une bronchite, telle qu’une bronchite aigue, une pneumopathie, telle qu’une pneumonie virale ou une pneumopathie liée au Sars-CoV-2.Therapeutic composition according to any one of the preceding claims, characterized in that the respiratory infection is chosen from influenza, a cold, bronchitis, such as acute bronchitis, pneumopathy, such as viral pneumonia or pneumopathy related to Sars-CoV-2.
- Composition thérapeutique sous forme d’ampoule de volume cinq millilitres à dix millilitres comprenant des huiles essentielles à faible doses, préférentiellement sous forme d’un mélange, et un excipient comprenant au moins une huile végétale comestible.Therapeutic composition in the form of an ampoule with a volume of five milliliters to ten milliliters comprising essential oils at low doses, preferably in the form of a mixture, and an excipient comprising at least one edible vegetable oil.
- Composition thérapeutique selon la revendication 14 caractérisée en ce que l’excipient est l’huile de sésame ou l’huile d’olive.Therapeutic composition according to Claim 14, characterized in that the excipient is sesame oil or olive oil.
- Composition thérapeutique selon la revendication 14 ou 15, caractérisée en ce que le mélange des huiles essentielles contient entre deux cent cinquante milligrammes et un gramme, préférentiellement entre 0,6 grammes et 1,0 gramme d’huiles essentielles à faible doses.Therapeutic composition according to Claim 14 or 15, characterized in that the mixture of essential oils contains between two hundred and fifty milligrams and one gram, preferably between 0.6 grams and 1.0 gram of essential oils at low doses.
- Composition thérapeutique selon l’une quelconque des revendications 14 à 16, caractérisée en ce que le mélange des huiles essentielles comprend une huile essentielle de menthe verte, le menthol, une huile essentielle de menthe aquatique, une huile essentielle de clous de girofle, une huile essentielle de menthe poivrée, une huile essentielle de menthe pouliot, une huile essentielle d’eucalyptus, une huile essentielle de cannelle, une huile essentielle de cajeput et du camphre, par exemple en cristaux ou sous forme d’huile essentielle de camphre.Therapeutic composition according to any one of Claims 14 to 16, characterized in that the mixture of essential oils comprises an essential oil of spearmint, menthol, an essential oil of water mint, an essential oil of cloves, an essential oil essential oil of peppermint, an essential oil of pennyroyal, an essential oil of eucalyptus, an essential oil of cinnamon, an essential oil of cajeput and camphor, for example in crystals or in the form of essential oil of camphor.
- Composition thérapeutique selon l’une quelconque des revendications 14 à 17, caractérisée en ce que le mélange des huiles essentielles comprend entre 0,04 et 0,08 grammes d’une huile essentielle de menthe verte, entre 0,05 et 0,09 grammes de menthol, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe aquatique, entre 0,02 et 0,06 grammes d’une huile essentielle de clous de girofle, entre 0,03 et 0,07 grammes d’une huile essentielle de menthe poivrée, entre 0,02 et 0,06 grammes d’une huile essentielle de menthe pouliot, entre 0,12 et 0,16 grammes d’une huile essentielle d’eucalyptus, entre 0,02 et 0,06 grammes d’une huile essentielle de cannelle, entre 0,04 et 0,08 grammes d’une huile essentielle de cajeput, entre 0,23 et 0,27 grammes de Camphre.Therapeutic composition according to any one of Claims 14 to 17, characterized in that the mixture of essential oils comprises between 0.04 and 0.08 grams of an essential oil of spearmint, between 0.05 and 0.09 grams of menthol, between 0.03 and 0.07 grams of an essential oil of water mint, between 0.02 and 0.06 grams of an essential oil of cloves, between 0.03 and 0.07 grams of a peppermint essential oil, between 0.02 and 0.06 grams a pennyroyal essential oil, between 0.12 and 0.16 grams a eucalyptus essential oil, between 0.02 and 0 0.06 grams of an essential oil of cinnamon, between 0.04 and 0.08 grams of an essential oil of cajeput, between 0.23 and 0.27 grams of Camphor.
- Composition thérapeutique selon l’une quelconque des revendications 14 à 18, comprenant 0,08 grammes d’une huile essentielle de menthe verte, 0,09 grammes de menthol, 0,07 grammes d’une huile essentielle de menthe aquatique, 0,06 grammes d’une huile essentielle de clous de girofle, 0,07 grammes d’une huile essentielle de menthe poivrée, 0,06 grammes d’une huile essentielle de menthe pouliot, 0,16 grammes d’une huile essentielle d’eucalyptus, 0,06 grammes d’une huile essentielle de cannelle, 0,08 grammes d’une huile essentielle de cajeput, 0,27 grammes de Camphre, par exemple en cristaux ou sous forme d’huile essentielle de camphre, et 9 grammes d’huile de sésame.Therapeutic composition according to any one of claims 14 to 18, comprising 0.08 grams of an essential oil of spearmint, 0.09 grams of menthol, 0.07 grams of an essential oil of water mint, 0.06 grams of clove essential oil, 0.07 grams of peppermint essential oil, 0.06 grams of pennyroyal essential oil, 0.16 grams of eucalyptus essential oil, 0.06 grams of an essential oil of cinnamon, 0.08 grams of an essential oil of cajeput, 0.27 grams of camphor, for example in crystals or in the form of essential oil of camphor, and 9 grams of Sesame oil.
- Composition thérapeutique selon l’une quelconque des revendications 14 à 19, pour son utilisation par voie orale pour le traitement des grippes, bronchites aigues et autres infections respiratoires.Therapeutic composition according to any one of Claims 14 to 19, for its use by the oral route for the treatment of influenza, acute bronchitis and other respiratory infections.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TNP/2020/000211A TN2020000211A1 (en) | 2020-11-03 | 2020-11-03 | NEW THERAPEUTIC COMPOSITION BASED ON LOW DOSE ESSENTIAL OILS |
PCT/IB2021/060180 WO2022097042A1 (en) | 2020-11-03 | 2021-11-03 | Novel therapeutic composition based on essential oils at low doses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4240387A1 true EP4240387A1 (en) | 2023-09-13 |
Family
ID=78819750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21816523.1A Pending EP4240387A1 (en) | 2020-11-03 | 2021-11-03 | Novel therapeutic composition based on essential oils at low doses |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4240387A1 (en) |
JP (1) | JP2023547722A (en) |
KR (1) | KR20230113318A (en) |
CN (1) | CN116546997A (en) |
AU (1) | AU2021374921A1 (en) |
CA (1) | CA3196828A1 (en) |
TN (1) | TN2020000211A1 (en) |
WO (1) | WO2022097042A1 (en) |
ZA (1) | ZA202305888B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7048953B2 (en) * | 2000-04-03 | 2006-05-23 | Inhalation, Inc. | Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS) |
-
2020
- 2020-11-03 TN TNP/2020/000211A patent/TN2020000211A1/en unknown
-
2021
- 2021-11-03 EP EP21816523.1A patent/EP4240387A1/en active Pending
- 2021-11-03 KR KR1020237018715A patent/KR20230113318A/en unknown
- 2021-11-03 JP JP2023527803A patent/JP2023547722A/en active Pending
- 2021-11-03 WO PCT/IB2021/060180 patent/WO2022097042A1/en active Application Filing
- 2021-11-03 CN CN202180080598.8A patent/CN116546997A/en active Pending
- 2021-11-03 CA CA3196828A patent/CA3196828A1/en active Pending
- 2021-11-03 AU AU2021374921A patent/AU2021374921A1/en active Pending
-
2023
- 2023-06-01 ZA ZA2023/05888A patent/ZA202305888B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3196828A1 (en) | 2022-05-12 |
CN116546997A (en) | 2023-08-04 |
TN2020000211A1 (en) | 2022-07-01 |
KR20230113318A (en) | 2023-07-28 |
JP2023547722A (en) | 2023-11-13 |
ZA202305888B (en) | 2023-12-20 |
AU2021374921A1 (en) | 2023-06-22 |
WO2022097042A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2155222B1 (en) | Extract of trigonella foenum-graecum | |
US20060127508A1 (en) | Preparation for the relief of disease | |
EP0022046A1 (en) | Drug composition based on plants and process for its preparation | |
WO2007014379A2 (en) | A lipidic extract from lepidium meynii and its effect on the libido | |
EP4240387A1 (en) | Novel therapeutic composition based on essential oils at low doses | |
Harris | 11 Phytotherapeutic Uses of Essential Oils | |
US20170020946A1 (en) | Analgesic compositions and methods of use | |
EP0722325B1 (en) | Composition for the treatment or prevention of herpes | |
RU2240131C1 (en) | Agent "artrovit" for prophylaxis and treatment of arthritis and arthrosis | |
DE102020131716A1 (en) | New therapy concept for the treatment of corona infections, especially COVID-19 infections | |
N’guessan et al. | Evaluation de la toxicité aiguë de Boerhavia diffusa chez la souris | |
JP7369931B2 (en) | Food and drink compositions for alleviating cold symptoms | |
DE102004063363A1 (en) | Composition for treatment and prevention of bronchial disease or allergy and for strengthening immune system, contains capsaicin or its derivatives | |
BATUBARA et al. | Evolving potential functional foods to meet modern needs in commercial product | |
TR2021007003A2 (en) | AN ANTIVIRAL AND ANTIBACTERIAL EFFECTIVE LAVENDER, CEDAR, CITRONELLA, MINT, PALMAROSA, Clove, CYPRESS AND LEMON ESSENTIAL OILS FOR NASAL AND ORAL USE. | |
FR3108036A1 (en) | Pharmaceutical or dietetic composition containing the aqueous extract of lavender and usable as an antidiabetic | |
FR2791892A1 (en) | Laxative compositions comprising an extract of senna rich in sennosides and, as carminative, powdered fruits of Illicium verum together with pharmaceutical excipients and diluents | |
TR2021006998A2 (en) | AN ANTIVIRAL AND ANTIBACTERIAL EFFECTIVE HERBAL COMPOSITION CONTAINING ESSENTIAL OILS OF LEMON, CYPRESS Eucalyptus AND Patchouli FOR NASAL AND ORAL USE | |
EP4216944A1 (en) | New therapy concept for the treatment of corona infections, more particularly covid-19 infections | |
OA21117A (en) | Phytomedicine for the treatment of colds and its manufacturing process. | |
FR2607006A1 (en) | Pharmaceutical composition based on Euphorbia pilulifera and/or hirta, used, in particular, as an intestinal disinfectant and/or cicatrising agent | |
FR2649615A1 (en) | Composition based on Simarouba glauca, used for the treatment, in particular, of psychological disorders and/or digestive disorders | |
FR3114005A3 (en) | repellent composition | |
JP2019214622A (en) | Oral composition | |
BRPI0806023A2 (en) | nasal antiseptic essential oil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230602 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAV | Requested validation state of the european patent: fee paid |
Extension state: MA Effective date: 20230602 |